Af­ter sting­ing FDA set­back, Glax­o­SmithK­line's Vi­iV fi­nal­ly notch­es US ap­proval for long-act­ing HIV in­jec­tion

5 years ago
FDA+

Months af­ter a ma­jor re­brand­ing around CAR-NKT cells, Ku­ur Ther­a­peu­tics is of­fer­ing a peek at ear­ly re­sults

5 years ago
R&D

De­val Patrick joins Cerev­el board, fur­ther in­ter­twin­ing com­pa­ny with Bain Cap­i­tal

5 years ago
People

North­way Biotech sets up shop in Boston hub, look­ing to court more cus­tomers with bi­o­log­ics-fo­cused plant

5 years ago
Manufacturing

News brief­ing: Five pub­lic biotechs, over 2 days, raise $883M from fresh of­fer­ings; Bel­gian biotech ex­pands Se­ries B ...

5 years ago
News Briefing

Covid-19 roundup: Flood, dead­ly fire threat­en As­traZeneca vac­cine plants; Italy won­ders aloud if it can sue Pfiz­er ...

5 years ago
Coronavirus

Plex­i­um adds in­dus­try vet Mike Grey to the brain trust with new in­vestor cash fund­ing its pro­tein degra­da­tion play

5 years ago
Financing

Eli Lil­ly's an­ti­body cuts risk of Covid-19 by up to 80% among the most vul­ner­a­ble — but will it have a place next ...

5 years ago
R&D
Coronavirus

End­points poll: Janet Wood­cock takes the (in­ter­im) helm at the FDA. And a large ma­jor­i­ty of our read­ers want her to ...

5 years ago
People
FDA+

With patent con­cerns loom­ing, Roche gets a new pri­or­i­ty re­view on block­buster IPF drug

5 years ago
R&D

BIO looks to re­struc­ture, lay­ing off staff amid chal­lenge to the trade org's nor­mal face-to-face style

5 years ago
Pharma

What’s next for End­points — and how to sup­port our in­de­pen­dent bio­phar­ma news mis­sion

5 years ago
Publisher's note

FDA guides on Covid-19 con­sid­er­a­tions in cell and gene ther­a­py

5 years ago
FDA+

Once laser-fo­cused on liv­er, Mi­NA takes swing at neu­rol­o­gy with Servier's back­ing

5 years ago
Deals

Pieris fi­nal­ly vaults FDA hold on next-gen sol­id tu­mor hunter, clear­ing the path for mid-stage tri­al

5 years ago
FDA+

News brief­ing: Ve­rastem CMO ex­its two weeks af­ter join­ing com­pa­ny; Ther­mo Fish­er inks $550M M&A deal

5 years ago
News Briefing

FDA hits the brakes on His­to­gen's knee car­ti­lage ther­a­py, ask­ing for more in­fo on man­u­fac­tur­ing process

5 years ago
FDA+

Grit­stone con­tin­ues Covid-19 push with deal to de­vel­op 'self-am­pli­fy­ing RNA' vac­cines, as shares con­tin­ue bal­loon­ing

5 years ago
Deals
Coronavirus

Bris­tol My­ers Squibb gets re­view date for Op­di­vo com­bo in gas­tric can­cer, look­ing to over­turn Keytru­da's 3-year lead

5 years ago
FDA+

Covid-19 claims an­oth­er PDU­FA vic­tim as Glax­o­SmithK­line push­es back planned PD-1 roll­out

5 years ago
FDA+

Bio­Med Re­al­ty snaps up in­no­va­tion cam­pus site with­in earshot of pricey and bustling Boston biotech hub

5 years ago
Pharma

Glax­o­SmithK­line's $4B bis­pe­cif­ic can­cer drug al­liance with Mer­ck KGaA hit by big set­back with a PhI­II fail­ure on ...

5 years ago
R&D

Paul Hud­son faces down French unions in fight to re­struc­ture Sanofi

5 years ago
Pharma

The IPO flood keeps ris­ing with 4 more biotechs and a SPAC on their way to Nas­daq

5 years ago
Financing
First page Previous page 753754755756757758759 Next page Last page
A service from the Financial Times